used, essentially independently, with little attempt at phasing the drug in relation to the radiation fractions. In fact the time relations of one to the other may be extremely critical. Vietti et al. (1971) have provided evidence that 5-FU potentiates the action of a single fraction of X-rays. These workers used the AkR mouse lymphoma and employed a technique to assay the residual clonogenic fraction of tumour cells following the combination regimen. They demonstrated potentiation of the radiation effect if 5-FU was given either 20 hours before the radiation fraction, or within the first 8 hours after the fraction, the latter effect being more pronounced. Clearly, in applying these observations to the development of a combined approach in man, the timing may differ and depend on differences between the cell population kinetics of the tumour and of the normal tissues. In their initial study Vietti and her colleagues did not examine the normal tissue response, although these studies are in progress (Vietti & Dale 1972) . In order to take advantage of short-term synergism between drug and radiation, modifications in radiation fractionation may be necessary, at least in part of the treatment, to allow the chemotherapeutic agent to be given with each fraction, while at the same time avoiding excessive damage to normal tissues (especially gut). The problem of adapting experimental observations to the clinical situation is difficult and probably best approached by examining the effects of single exposures of drug and radiation on lung or skin metastases where volume changes are quantifiable. 
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Chemotherapy in Colorectal Cancer
Although many drugs have been given in different ways to patients with advanced colorectal cancer there is little evidence that chemotherapy prolongs life, except in a few. For example, in a series of 353 patients with liver metastases reported by Pestana et al. (1964) who received no chemotherapy the median survival was 9 months. In a similar series of 61 patients reported by Rapoport & Burleson (1970) who did receive chemotherapy the median survival was 8.5 months.
However, chemotherapy may improve the quality oflife ofpatients with colorectal metastases and every chemotherapist is familiar with the pain relief and increase in general well-being which may result from the judicious use of cytotoxic drugs. A prime example is the use of 5fluorouracil (5-FU) or fluorodeoxyuridine given intraarterially to relieve the pain of hepatic metastases (Watkins et al. 1970) . In general there is little indication to give chemotherapy to asymptomatic patients with advanced disease, but the presence of pain, abdominal discomfort and distension, loss of weight, anorexia and nausea are indications for a trial of chemotherapy.
Drugs may be given as single agents or in combinations.
Single Agents Some commonly used drugs are described:
Chlorambucil was used to treat 55 patients by Moore et al. (1968) . Five patients (9.1 %) responded, one of whom had a complete remission. The dose was 0.2 mg/kg/day for up to 42 days.
Cyclophosphamide: The overall response rate with cyclophosphamide is about 16%. Several authors (Foye et al. 1960 , Coggins et al. 1960 , Hurley et al. 1961 , Wall & Conrad 1961 , Gold et al. 1970 have described a variety of dosage regimes in a total of 43 patients. None of these patients achieved complete remission and no remission lasted longer than 4 months.
Nitrogen mustard in standard dosage appears to be about as effective as cyclophosphamide (Rhoades 1948 , Ariel & Kanter 1949 , Hurley & Ellison 1960 , Gold et al. 1970 ) and has the disadvantage that it causes intense nausea and vomiting.
Vincristine used alone seems to have no influence on colorectal cancer (Costa et al. 1962 , Shaw & Bruner 1964 although no, large series of patients has been reported. Despite this, vincristine has been included in a number of drug combinations where it is probably of no benefit.
Carmustine (1, 3-bis (2-chloroethyl)-1 nitrosourea; BCNU): This recently introduced drug has been used by Moertel et al. (1968) to treat gastrointestinal cancer. Nine patients out of 72 responded (12.5 %). The mean response length was 19 weeks compared with a response rate of 17 % in 290 patients treated with 5-FU whose mean length of response was 8 months.
Methotrexate has been used in a variety of different schedules. These may be divided arbitrarily into low dose regimes (Schoenbach et al. 1952 , Wilson & Louis 1965 , Sullivan et al. 1967 ) and high dose regimes (Condit et al. 1962 , Eastern Cooperative Group in Solid Tumour Chemotherapy 1967 , Andrews & Wilson 1967 . The overall response rate was about 15 % and there was no significant difference between the response rates for the high and low dose regimes.
S-Fluorouracil (S-FU):
The use of 5-FU in gastrointestinal cancer has recently been well reviewed by Kaufman (1973) , and Livingstone & Carter (1970) have published the accumulated experience of many authors in the treatment of 1255 patients with colorectal cancer. The response rate is about 24 %, histological grade of tumour does not influence response and objective responses do not usually last more than 3 or 4 months. More than half the patients experience some toxicity which may be manifest as diarrhoea (60%), neutropenia (40 %) or stomatitis (30 %O). The original regime of Curreri et al. (1958) , in which a large 'loading dose' of 5-FU is given intravenously, is not superior to the lower dosage schedule of Jacobs et al. (1968) , where 15 mg/kg is given intravenously for 4 weeks followed by 20 mg/kg intravenously weekly until signs of mild toxicity appear. Futhermore, Khung et al. (1966) have shown that the drug is just as effective if given by mouth in fruit juice, which further simplifies its administration.
There seems little doubt that 5-FU is the best single agent for the treatment ofcolorectal cancer.
Combination Chemotherapy
It has become a touchstone of modern cancer chemotherapy that combinations of drugs are likely to be more effective than single agents (Henderson & Samaha 1969 , Frei 1972 . This is certainly true of sensitive tumours such as leuklmia and lymphomas, but it is not at present true of colorectal cancer. Various different combinations have been advocated:
(1) 5-FU and vinblastine (Al-Sarraf et al. 1972 ): response 6 %.
(2) 5-FU, mitomycin C, vincristine and thiotepa (Horton et al. 1965) : response 17 %.
(3) 5-FU, mitomycin C and BCNU ): response 5.5 % (5-FU alone: 25 %). (4) Cyclophosphamide, vincristine, methotrexate and 5-FU (Costanzi & Coltman 1969) : this combination is now widely used although no patient with colorectal cancer responded in the original series.
Conclusions
(1) 5-FU is the drug of choice in colorectal cancer.
(2) Toxic doses of 5-FU are not required to produce responses.
(3) Combinations are not superior to 5-FU alone but are probably more toxic.
(4) There is no evidence that high-dose chemotherapy is superior to low-dose treatment.
(5) There is little evidence that chemotherapy prolongs surivival but it may improve quality of life. (6) Advances in chemotherapy will probably depend on a better understanding of the biology of the tumours, and in particular their proliferative characteristics and the biochemical mechanisms of their innate or acquired resistance to drugs.
Dr L A Price (Division ofMedicine, Royal Marsden Hospital, London SW3 6JJ)
Possible Approaches to the Chemotherapy of Gut Cancer Possible approaches towards improving the poor results of the chemotherapy of gut cancer may be considered under two headings: clinical and experimental. Clinically it might be helpful if cases were studied at special centres, as advocated by York Mason (1973) , where techniques such as radioisotope scanning, lymphography and monitoring of tumour index substances could be carried out. This would facilitate accurate staging of the disease, and enable the various stages to be correlated with therapeutic response, so forming a base-line against which new agents might be tested clinically. One such system has been described at the Memorial Sloan-Kettering Cancer Center, New York (Young et al. 1960 ).
Since 5-fluorouracil (5-FU) is the only drug which produces a consistent response, it should always be considered provided it is given optimally, i.e. as a single intravenous injection once every week or two weeks. There are valid reasons, theoretical (Bruce et al. 1966 ) and practical (Jacobs et al. 1971) , for this dose schedule. The practice of giving the drug daily for several days or until toxicity supervenes should be abandoned; it has no therapeutic advantage and often makes the patient worse than he would be without treatment. In bad-risk cases it is logical to start the drug when the number of malignant cells is smallest, i.e. immediately after surgery.
Even if these suggestions were adopted, however, 80 % of patients with inoperable gut cancer would fail to respond to drug therapy now available.
Since giving combinations of existing agents does not appear to improve results, the overriding need in gut cancer is for newer and more effective drugs, and the basic question therefore is how such drugs may be developed. Experimentally, it is important to discover what agents kill resistant cells. There are at least two systems which may be helpful. The first, used by Dr Leon Cobb in Professor A M Neville's department at the Chester Beatty Research Institute, and also at other centres, involves taking the tumour from the patient at operation and transplanting it into immunologically deprived mice (L M Cobb 1973, personal communication). The tumour grows in such animals, and has the same histological features and mitotic index as the original tumour. It can be retransplanted into successive generations of thymectomized or irradiated mice. New agents could easily be screened in this approximation system. Another way of finding out whether resistant cells can be killed is to use a line of cells in tissue culture which are resistant to 5-FU. This sytem is simple to use and could screen new agents very rapidly.
Intracellular studies on the 'how' and 'why' of cell death, such as disturbances in nucleotide pools, &c., have been under way for at least fifteen years and have made no contribution to any practical clinical problem. Even if such studies are carried out on histologically and kinetically heterogeneous human tumour cells, I think they are unlikely to be helpful for many years.
It seems to me that improvements in the chemotherapy of gut cancer, as with other tumours, are most likely to occur gradually and empirically by testing new agents in patients. Drugs of suggestive clinical value at present are CCNU (a nitrosourea), VM26 (a podophyllin derivative) and possibly 5-azacytidine (a derivative of cytosine arabinoside). Finally, although gut cancer occurs twice as commonly as the leukemias and lymphomas put together, it attracts only one-tenth as many research contributions. Perhaps progress would be quicker if more people worked on the problem.
